Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer-Reference-Cited by-同舟云学术

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

Published:2012-03 Issue:3 Volume:23 Page:625-631
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Albanell J.,González A.,Ruiz-Borrego M.,Alba E.,García-Saenz J.A.,Corominas J.M.,Burgues O.,Furio V.,Rojo A.,Palacios J.,Bermejo B.,Martínez-García M.,Limon M.L.,Muñoz A.S.,Martín M.,Tusquets I.,Rojo F.,Colomer R.,Faull I.,Lluch A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/3/625/606631/mdr278.pdf

Reference33 articles.

1. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer;Goldhirsch;Ann Oncol,2009

2. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up;Aebi;Ann Oncol,2010

3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials;Lancet,2005

4. Measurement of gene expression in archival paraffin-embedded tissues;Cronin;Am J Pathol,2004

5. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer;Cronin;Clin Chem,2007

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer;Breast Cancer Research and Treatment;2024-06-14

2. NONHSAT021545/miR-330-3p/EREG: A Cooperative Axis in Breast Cancer Prognosis and Treatment;Journal of Clinical Medicine;2023-03-24

3. Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study;Cancers;2023-02-28

4. The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing;Cancers;2023-01-31

5. Efficacy of chemotherapy in patients with HR+/HER2–Invasive lobular breast cancer;Cancer Treatment and Research Communications;2023